932 results match your criteria Drug-Induced Pulmonary Toxicity


Effective Gold Nanoparticle-Antibody-Mediated Drug Delivery for Photodynamic Therapy of Lung Cancer Stem Cells.

Int J Mol Sci 2020 May 26;21(11). Epub 2020 May 26.

Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, P.O. Box 17011, Doornfontein, Johannesburg 2028, South Africa.

Cancer stem cells (CSCs) are a leading contributor to lung cancer mortality rates. CSCs are responsible for tumor growth and recurrence through inhibition of drug-induced cell death, decreasing the effect of traditional cancer therapy and photodynamic therapy (PDT). PDT can be improved to successfully treat lung cancer by using gold nanoparticles (AuNPs), due to their size and shape, which have been shown to facilitate drug delivery and retention, along with the targeted antibody (Ab) mediated selection of CSCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21113742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311980PMC

Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis.

Rheumatology (Oxford) 2020 May 14. Epub 2020 May 14.

Central Clinical School, Monash University, Melbourne.

Objectives: Small molecule tyrosine kinase inhibitors [smTKI, comprising mostly of Janus kinase (JAK) and to a lesser extent, spleen tyrosine kinase (SyK) inhibitors] modulate the cytokine receptor-mediated intracellular signal cascade, and are an effective treatment for autoimmune diseases and malignancies. As smTKI are novel, long-term safety is uncertain. Due to increasing use, characterization of their true adverse event profile is critical. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/keaa117DOI Listing

Radiological patterns of drug induced interstitial lung disease (DILD) in early phase oncology clinical trials.

Clin Cancer Res 2020 Apr 24. Epub 2020 Apr 24.

Drug Development Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research

Purpose: Drug induced interstitial lung disease (DILD) is a rare, but potentially fatal toxicity. Clinical and radiological features of DILD in the early experimental setting are poorly described.

Experimental Design: 2499 consecutive advanced cancer patients on phase I clinical trials were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-0454DOI Listing

HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review.

Diagnostics (Basel) 2020 Apr 22;10(4). Epub 2020 Apr 22.

Radiology Unit 1, Department of Medical Surgical Sciences and Advanced Technologies "GF Ingrassia"-University Hospital "Policlinico-Vittorio Emanuele", University of Catania, 95123 Catania, Italy.

Interstitial Lung Diseases (ILDs) represent a heterogeneous group of pathologies, which may be related to different causes. A low percentage of these lung diseases may be secondary to the administration of drugs or substances. Through the PubMed database, an extensive search was performed in the fields of drug toxicity and interstitial lung disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics10040244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236658PMC

Drug induced lung toxicity by nitrofurantoin

Cas Lek Cesk 2020 ;159(1):35-37

We present the clinical case of the patient with nitrofurantoin (FUR) lung toxicity. Diagnosis was made from detailed history of the patient and by studying CT images before the start of FUR treatment. An extensive interstitial changes were evident on HRCT scan at the presentation at our clinic. Read More

View Article

Download full-text PDF

Source
January 2020

Panitumumab-Induced Eruptive Seborrhoeic Keratosis in a Patient with Metastatic Colorectal Cancer.

Eur J Case Rep Intern Med 2020 15;7(2):001411. Epub 2020 Jan 15.

Dermatology Department, University Hospital of Heraklion, PAGNI, Heraklion, Crete, Greece.

Objectives: Agents targeting the epidermal growth factor receptor (EGFR)-mediated signalling pathway are increasingly being used for the treatment of advanced lung, pancreatic, colorectal and head and neck cancers.

Case Presentation: Here, we report the first case of eruptive seborrhoeic keratosis following panitumumab treatment, an anti-EGFR monoclonal antibody, in a 73-year-old patient with stage 4 (IV) colorectal cancer with hepatic metastasis.

Conclusion: While panitumumab is an emerging therapy for RAS wild-type metastatic colorectal cancer, physicians should consider panitumumab as a potential cause of eruptive seborrhoeic keratosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2020_001411DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050975PMC
January 2020

Diffuse alveolar hemorrhage after gadolinium injection during a MRI.

Respir Med Case Rep 2020 6;29:101021. Epub 2020 Feb 6.

Service du département d'aval des urgences, Hôpital Henri Mondor, AP HP, 94000, Créteil, France.

Gadolinium is a frequently used contrast product for MRI exam. It is well known to be less immuno-reactive than iodine used in tomodensitometry but is safety is not completely exempt of secondary effect. Here we report one case of acute interstitial pulmonary toxicity due to gadolinium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2020.101021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016271PMC
February 2020

Consider Nitrofurantoin as a Cause of Lung Injury.

Eur J Case Rep Intern Med 2019 30;6(11):001295. Epub 2019 Oct 30.

Department of Internal Medicine Centro Hospitalar Baixo Vouga, Aveiro, Portugal.

Nitrofurantoin-induced diffuse lung toxicity is well documented in the literature but is often misdiagnosed. We describe an 82-year-old female medicated with nitrofurantoin for the previous 2 years who was admitted for dyspnoea, dry cough and fatigue for 4 months. She was febrile and tachypnoeic and she presented with bilateral basal crackles, hypoxaemic respiratory failure and slightly elevated C-reactive protein levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2019_001295DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886637PMC
October 2019

Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.

In Vivo 2020 Jan-Feb;34(1):315-319

Veterans Affairs North Texas Healthcare System, Dallas, TX and Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.

Osimertinib is an oral, irreversible epidermal growth factor receptor inhibitor that is associated with various pulmonary manifestations including transient asymptomatic pulmonary opacities (TAPOs) and pneumonitis. We present a case of a 61-year-old female with Stage IV lung adenocarcinoma, who developed bilateral ground glass opacities on her chest-computed tomography (CT) three months after initiating osimertinib. Her imaging findings were thought to represent lymphangitic carcinomatosis responding to chemotherapy rather than drug induced toxicity, and she was continued on osimertinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/invivo.11776DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984067PMC

Acetaminophen increases pulmonary and systemic vasomotor tone in the newborn rat.

Pediatr Res 2020 Jun 12;87(7):1171-1176. Epub 2019 Dec 12.

Translational Medicine Program, Department of Paediatrics, The Hospital for Sick Children Research Institute, Toronto, ON, M5G 1X8, Canada.

Background: Acetaminophen is widely prescribed to both neonates and young children for a variety of reasons. In adults, therapeutic usage of acetaminophen induces systemic arterial pressure changes and exposure to high doses promotes tissue toxicity. The pulmonary vascular effects of acetaminophen at any age are unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41390-019-0725-9DOI Listing

Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.

Rheumatology (Oxford) 2019 12;58(Suppl 7):vii17-vii28

Division of Digestive Diseases, Faculty of Medicine, Imperial College London, UK.

Immune check point inhibitor (CPI) therapy has revolutionized treatment paradigms for several cancers, but at the cost of triggering a diverse spectrum of immune-mediated injury to non-cancer tissues. The complex biology of these toxicities remains incompletely understood, partly because tissue acquisition from affected areas can be challenging to retrieve, thus hindering development of targeted therapy. Here, we review the literature describing pathology of immune-mediated tissue lesions including gastrointestinal, skin, rheumatic, pulmonary, cardiac, renal and hepatic lesions and highlight key immunological insights. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kez465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900915PMC
December 2019

Evaluation of biological activities and in vivo amelioration of CCl induced toxicity in lung and kidney with Abutilon pannosum (G.Forst.) Schltdl. in rat.

J Ethnopharmacol 2020 Mar 15;249:112395. Epub 2019 Nov 15.

Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, 45320, Pakistan. Electronic address:

Ethnopharmacological Relevance: Abutilon pannosum is used in Pakistan for bladder inflammation, diuretic, lung disorders, diabetes and in lowering pyrexia.

Methods: Amount of total phenolic content, total flavonoid content and HPLC analysis of APM for the presence of polyphenolics were carried out. Antioxidant activity was determined by using different in vitro antioxidant assays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jep.2019.112395DOI Listing

Amlexanox ameliorates acetaminophen-induced acute liver injury by reducing oxidative stress in mice.

Toxicol Appl Pharmacol 2019 12 5;385:114767. Epub 2019 Nov 5.

Biosafety Research Institute and Laboratory of Pathology (BK21 Plus Program), College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea. Electronic address:

Amlexanox, a clinically approved small-molecule therapeutic presently used to treat allergic rhinitis, ulcer, and asthma, is an inhibitor of the noncanonical IkB kinase-ε (IKKε) and TANK-binding kinase 1 (TBK1). This study was to investigate the protective mechanism of amlexanox in acetaminophen (APAP)-induced acute liver injury (ALI). Mice were intraperitoneally injected with APAP (300 mg/kg, 12 h) to induce ALI and were orally administrated with amlexanox (25, 50 and 100 mg/kg) one hour after APAP treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.taap.2019.114767DOI Listing
December 2019

Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients.

Mult Scler Relat Disord 2020 Jan 15;37:101450. Epub 2019 Oct 15.

Multiple Sclerosis Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia. Institute of Neurology, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli n 8, 00168 Rome, Italia.

Background: Respiratory alemtuzumab-related adverse events are clinically heterogeneous and include respiratory infections, infusion-related dyspnea, hypoxia and secondary autoimmune disorders.

Case Report: Here we report three cases of drug-induced lung disease following treatment with alemtuzumab in multiple sclerosis patients. First case was diagnosed as a non-specified intestitial pneumonitis associated with organizing pneumonia with subacute onset, second case was an acute respiratory distress syndrome with onset during second cycle, third case was a diffuse acute alveolar hemorrhage during first cycle infusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2019.101450DOI Listing
January 2020
2 Reads

Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.

Immunology 2020 02 19;159(2):167-177. Epub 2019 Nov 19.

Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK.

Immune checkpoint inhibition with monoclonal antibodies is becoming increasingly commonplace in cancer medicine, having contributed to a widening of therapeutic options across oncological indications. Disruption of immune tolerance is the key mechanism of action of checkpoint inhibitors and although immune-related adverse events are a typical class effect of these compounds, the relationship between toxicity and response is not fully understood. Awareness and vigilance are paramount in recognizing potentially life-threatening toxicities and managing them in a timely manner. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imm.13141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954715PMC
February 2020

Carbon monoxide ameliorates acetaminophen-induced liver injury by increasing hepatic HO-1 and Parkin expression.

FASEB J 2019 12 23;33(12):13905-13919. Epub 2019 Oct 23.

Department of Biological Sciences, University of Ulsan, Ulsan, South Korea.

Acetaminophen (APAP) is widely used as an antifebrile and analgesic drug at recommended doses, whereas an overdose of APAP can cause severe liver damage. The molecular mechanisms underlying APAP-induced liver damage remain incompletely understood. Carbon monoxide (CO), an end-product of heme oxygenase (HO)-1 activity, can confer anti-inflammatory and antiapoptotic properties in cellular models of toxicity regulation of mitochondrial function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.201901258RRDOI Listing
December 2019

[Effects of Tripterygium Glycosides Tablets from 6 different manufacturers on acute liver injury of normal mice].

Zhongguo Zhong Yao Za Zhi 2019 Aug;44(16):3494-3501

Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences Beijing 100700,China.

The aim of this paper was to compare the performance of acute liver injury in mice induced by Tripterygium Glycosides Tablets from 6 different manufacturers,and to explore the toxicity mechanism from the perspective of oxidative stress and apoptosis preliminarily. Male or female mice were randomly divided into normal group,Zhejiang group,Hunan group,Hubei group,Shanghai group,Jiangsu group and Fujian group. Mice in Tripgerygium Glycosides Tablets groups were given 16 times the clinical equivalent dose( 300 mg·kg-1) Tripgerygium Glycosides Tablets by oral administration for one time,mice were executed in 24 h after lavaged. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19540/j.cnki.cjcmm.20190715.401DOI Listing
August 2019
2 Reads

Pulmonary function testing for the early detection of drug induced lung disease: a systematic review in adults treated with drugs associated with pulmonary toxicity.

Intern Med J 2019 Oct 7. Epub 2019 Oct 7.

Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia.

Introduction: Pulmonary function tests (PFT) are sometimes monitored during treatment with known pulmonary toxic drugs to detect asymptomatic drug induced interstitial lung disease (DILD). We conducted a systematic review to assess the accuracy of PFTs, including the diffusing capacity for carbon monoxide (DLCO), for early detection of DILD in a range of drugs.

Methods: Using a pre-specified, registered review protocol, OvidMEDLINE and EMBASE were searched from 1946 to February 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.14647DOI Listing
October 2019
1 Read

Chrysin enhances anticancer drug-induced toxicity mediated by the reduction of claudin-1 and 11 expression in a spheroid culture model of lung squamous cell carcinoma cells.

Sci Rep 2019 09 24;9(1):13753. Epub 2019 Sep 24.

Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.

The aberrant expression of claudins (CLDNs), which are tight junctional proteins, is seen in various solid tumors, but the regulatory mechanisms and their pathophysiological role are not well understood. Both CLDN1 and CLDN11 were highly expressed in human lung squamous cell carcinoma (SCC). Chrysin, found in high concentration in honey and propolis, decreased CLDN1 and CLDN11 expression in RERF-LC-AI cells derived from human lung SCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-50276-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760125PMC
September 2019
1 Read

Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach.

Toxicol Sci 2019 12;172(2):265-278

Department of Genetics.

Idelalisib is a phosphatidylinositol 3-kinase inhibitor highly selective for the delta isoform that has shown good efficacy in treating chronic lymphocytic leukemia and follicular lymphoma. In clinical trials, however, idelalisib was associated with rare, but potentially serious liver and lung toxicities. In this study, we used the Collaborative Cross (CC) mouse population to identify genetic factors associated with the drug response that may inform risk management strategies for idelalisib in humans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/toxsci/kfz199DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876541PMC
December 2019
1 Read

A case report of phenytoin-induced eosinophilic pneumonia.

Respir Med Case Rep 2019 11;28:100922. Epub 2019 Aug 11.

Department of Pulmonary and Critical Care, University of Texas Southwestern Medical Center, USA.

Eosinophilic pneumonia comprises a rare and potentially serious group of lung diseases characterized by abnormal accumulation of eosinophils in the lungs. Many medications including the anticonvulsant phenytoin, have been implicated in the development of eosinophilic pneumonia. Attributing eosinophilic pneumonia to a medication or toxin can be difficult and may only be achieved by exclusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2019.100922DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710233PMC
August 2019
1 Read

A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity.

Tuberculosis (Edinb) 2019 07 24;117:79-84. Epub 2019 Jun 24.

Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India.

Bedaquiline was approved by USFDA in 2012 for pulmonary MDR-TB. The IC value of bedaquiline was reported to be remarkably low (25 nM), effectively inhibiting mycobacterial ATP synthase. In addition to these obvious assets of bedaquiline, the potential disadvantages of bedaquiline include inhibition of the hERG (human Ether-à-go-related gene; KCNH) potassium channel (concurrent risk of cardiac toxicity), hepatic toxicity and possibly phospholipidosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tube.2019.06.005DOI Listing
July 2019
5 Reads

Thoracic Manifestations of Rheumatoid Arthritis.

Clin Chest Med 2019 09 6;40(3):545-560. Epub 2019 Jul 6.

Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, MA 02115, USA. Electronic address:

Rheumatoid arthritis (RA) is commonly associated with pulmonary disease that can affect any anatomic compartment of the thorax. The most common intrathoracic manifestations of RA include interstitial lung disease, airway disease, pleural disease, rheumatoid nodules, and drug-induced toxicity. Patients with RA with thoracic involvement often present with nonspecific respiratory symptoms, although many are asymptomatic. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S02725231193003
Publisher Site
http://dx.doi.org/10.1016/j.ccm.2019.05.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994971PMC
September 2019
7 Reads

Drug-induced interstitial lung disease: role of pharmacogenetics in predicting cytotoxic mechanisms and risks of side effects.

Curr Opin Pulm Med 2019 09;25(5):468-477

ILD Care Foundation Research Team, Ede, The Netherlands.

Purpose Of Review: The diagnosis of drug-induced interstitial lung disease (DI-ILD) is challenging and mainly made by exclusion of other possible causes. Toxicity can occur as a cause of drug(s) or drug-drug interactions. In this review, we summarize the possible role of pharmacogenetics of metabolizing enzymes in DI-ILD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCP.0000000000000590DOI Listing
September 2019
3 Reads

Hepatotoxicity of immune check point inhibitors: Approach and management.

Dig Liver Dis 2019 08 8;51(8):1074-1078. Epub 2019 Jul 8.

Humanitas Clinical and Research Center IRCCS, Rozzano, MI, Italy. Electronic address:

Therapeutic reversal of immune tolerance following immune checkpoint inhibitors (ICPI) administration, has proven effective in prolonging survival of patients with a variety of solid and liquid tumors, often however at the expenses of discrete toxicities known as immune-related adverse events (AEs). Such reactions result from activation of the immune system and often present with generalized symptoms including fatigue or fever and, in some patients, may cause organ-specific damage. Skin, gut, endocrine, lung and musculoskeletal are the most frequent targets of ICPI toxicity whereas, cardiovascular, hematologic, renal, neurologic and ophthalmologic AEs occur much less frequently. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dld.2019.06.017DOI Listing
August 2019
2 Reads

The HtrA3 protease promotes drug-induced death of lung cancer cells by cleavage of the X-linked inhibitor of apoptosis protein (XIAP).

FEBS J 2019 11 11;286(22):4579-4596. Epub 2019 Jul 11.

Department of General and Medical Biochemistry, Faculty of Biology, University of Gdansk, Poland.

HtrA3 is a proapoptotic protease shown to promote drug-induced cytotoxicity in lung cancer cells and proposed to have an antitumor effect. However, at the molecular level, the role of HtrA3 in cell death induction is poorly understood. There are two HtrA3 isoforms, a long and a short one, termed HtrA3L and HtrA3S. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/febs.14977DOI Listing
November 2019

Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient.

Front Pharmacol 2019 11;10:645. Epub 2019 Jun 11.

Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland.

We will present a 42-year-old woman with acute myeloid leukemia and pulmonary aspergillosis. She was treated with several antifungal agents, including three triazoles. Voriconazole, posaconazole, and isavuconazole all led to hepatocellular liver injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.00645DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580185PMC
June 2019
7 Reads

Endothelin receptor antagonism during preeclampsia: a matter of timing?

Clin Sci (Lond) 2019 06 20;133(12):1341-1352. Epub 2019 Jun 20.

Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

Preeclampsia (PE) is a pregnancy complication, featuring elevated blood pressure and proteinuria, with no appropriate treatment. Activation of the endothelin system has emerged as an important pathway in PE pathophysiology based on experimental PE models where endothelin receptor antagonists (ERAs) prevented or attenuated hypertension and proteinuria. Hence, ERAs have been suggested as potential therapy for PE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/CS20190464DOI Listing
June 2019
15 Reads

A comprehensive review of cytochrome P450 2E1 for xenobiotic metabolism.

Drug Metab Rev 2019 05 28;51(2):178-195. Epub 2019 Jun 28.

School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University , Guangzhou , China.

Cytochrome P450 2E1 (CYP2E1) plays a vital role in drug-induced hepatotoxicity and cancers (e.g. lung and bladder cancer), since it is responsible for metabolizing a number of medications and environmental toxins to reactive intermediate metabolites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03602532.2019.1632889DOI Listing
May 2019
9 Reads

Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial.

Gastroenterol Hepatol Bed Bench 2019 ;12(2):138-142

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Aim: This study was performed to evaluate the potential efficacy of silymarin in the management of anti-tuberculosis medication's induced liver injury.

Background: Hepatic toxicity is the most serious complication in treatment of tuberculosis.

Methods: In a randomized double blind clinical trial (ACTRN12610000643077), 55 cases with hepatotoxicity caused by anti-tuberculosis drugs were divided into two groups. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536020PMC
January 2019
18 Reads

Fetal methotrexate syndrome: A systematic review of case reports.

Reprod Toxicol 2019 08 8;87:125-139. Epub 2019 Jun 8.

Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Methotrexate is a folic acid antagonist known to be teratogenic in humans. Several cases of congenital malformations after fetal exposure to methotrexate have been published, resulting in the establishment of the 'fetal methotrexate syndrome'. However, it is unclear which congenital anomalies can truly be attributed to methotrexate exposure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.reprotox.2019.05.066DOI Listing
August 2019
19 Reads

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma.

Intern Med 2019 Sep 7;58(18):2651-2655. Epub 2019 Jun 7.

Department of Medical Oncology, Izumi City General Hospital, Japan.

Crizotinib has been approved for patients with advanced lung adenocarcinoma harboring rearrangements of the c-ROS-1 (ROS1) and anaplastic lymphoma kinase (ALK) genes. We report a patient with ROS1-rearranged lung adenocarcinoma who developed a crizotinib-induced mixed/cholestatic type of liver injury. The patient discontinued crizotinib after 34 days due to liver toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2554-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794186PMC
September 2019

Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells.

Toxicology 2019 08 4;424:152231. Epub 2019 Jun 4.

Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan. Electronic address:

Many drugs exert serious cytotoxic effects on pulmonary tissues. Although several reports have shown an association of epithelial-mesenchymal transition (EMT) with anticancer drug-induced lung injury, mechanisms of these effects are poorly understood. In the present study, we evaluated mechanisms of anticancer drug-induced EMT, with a focus on involvement of cell cycle arrest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tox.2019.06.002DOI Listing
August 2019
1 Read

The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment.

Rheumatology (Oxford) 2019 11;58(11):2031-2038

Center for Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK.

Objectives: Lung involvement in RA has several manifestations and is a major cause of morbidity and mortality. The aim of this study was to characterize the different types of lung disease and response to treatment in a UK cohort of RA patients.

Methods: RA patients who had undergone high resolution CT scans of the lung were identified and scans reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kez177DOI Listing
November 2019
4 Reads

Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice.

Int J Rheum Dis 2019 Jul 22;22(7):1226-1232. Epub 2019 Apr 22.

Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden.

Aim: To assess predictors of alanine aminotransferase (ALT) elevation in methotrexate (MTX) treated rheumatoid arthritis (RA) patients, and to describe the monitoring of liver enzymes, including handling and outcome of elevated ALT.

Methods: All RA patients starting MTX in January, 2005 to April, 2013 at a rheumatology clinic, (Uppsala University Hospital, Sweden) were identified from electronic medical records. Clinical and laboratory data were obtained from medical records, supplemented by telephone interviews. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13576DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767545PMC

Low-dose methotrexate toxicity.

CMAJ 2019 04;191(15):E423

Department of Medicine (Pivovarov, Zipursky), University of Toronto; Division of Internal Medicine (Pivovarov), Mount Sinai Hospital; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1503/cmaj.181054DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464879PMC

Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.

Anticancer Drugs 2019 08;30(7):e0764

Pulmonary Oncology Unit.

In the last few years, immunotherapy has become part of everyday clinical practice for the treatment of many solid tumors including metastatic non-small-cell lung cancer. These drugs, however, can yield a specific toxicity profile that consists of immune-related adverse events (irAEs). Hepatotoxicity is one of irAEs and occurs in about 1-3% of cases and may be manifested by the presence of increate levels of liver enzymes (aspartate aminotransferase, alanine aminotransferase) and/or biliary stasis evidence; in these cases, a differential diagnosis with other hepatic diseases must be considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000764DOI Listing
August 2019
15 Reads

Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer.

Acta Med Port 2019 Mar 29;32(3):236-239. Epub 2019 Mar 29.

Serviço de Medicina Interna. Hospital Prof Doutor Fernando da Fonseca. Amadora. Portugal.

The treatment of advanced non-small-cell lung cancer shifted with the development of molecular-targeted therapies, like the tyrosine kinase inhibitors. One example of tyrosine kinase inhibitors is crizotinib, an anaplastic lymphoma tyrosine kinase inhibitor, which targets an echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase gene fusion. This mutation is found in only 2% to 7% of non-small-cell lung cancer cases. Read More

View Article

Download full-text PDF

Source
https://www.actamedicaportuguesa.com/revista/index.php/amp/a
Publisher Site
http://dx.doi.org/10.20344/amp.9456DOI Listing
March 2019
26 Reads

variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis.

Int J Tuberc Lung Dis 2019 03;23(3):293-305

Department of Biostatistics, University of Liverpool, Liverpool.

Background: Tuberculosis (TB) patients receiving anti-tuberculosis treatment may experience serious adverse drug reactions (ADRs) such as hepatotoxicity. Variants of the -acetyltransferase 2 () gene may increase the risk of experiencing such toxicity events.

Objective: To provide a comprehensive evaluation of the evidence base for associations between variants and anti-tuberculosis drug-related toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5588/ijtld.18.0324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421944PMC
March 2019
1 Read

Quantitative MALDI Imaging of Spatial Distributions and Dynamic Changes of Tetrandrine in Multiple Organs of Rats.

Theranostics 2019 25;9(4):932-944. Epub 2019 Jan 25.

State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.

Detailed spatio-temporal information on drug distribution in organs is of paramount importance to assess drug clinically-relevant properties and potential side-effects. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) as a label-free and sensitive imaging modality provides an additional means of accurately visualizing drug and its metabolites distributions in tissue sections. However, technical limitations, complex physiochemical environment of surface and low abundance of target drugs make quantitative MALDI imaging of drug and its metabolites quite challenging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.30408DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401406PMC
January 2020
9 Reads

Bleomycin-Induced Cryptogenic Organizing Pneumonia Manifested as Spontaneous Pneumothorax in a Patient with Classic Seminoma.

Tanaffos 2019 Mar;18(3):268-271

Departamento de Neumología y Cirugía de Tórax. Hospital Regional de Alta Especialidad de la Península de Yucatán.

Cryptogenic Organizing Pneumonia (COP) can manifest like a collagen disorder or infectious diseases, or be caused by drug induced toxicity. This paper presents the case of a 24 year-old man diagnosed with classic seminoma, treated with chemotherapy scheme that included bleomycin (accumulated dose, 120 units). The patient was admitted at the hospital due to rapidly-progressing dyspnea and thoracic pain. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210568PMC

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.

Invest New Drugs 2019 12 21;37(6):1207-1217. Epub 2019 Feb 21.

Thoracic Center, St. Luke's International Hospital, 9-1 Akashicho, Chuo-ku, Tokyo, 104-0045, Japan.

Purpose We investigated the safety, tolerability, pharmacokinetics, and efficacy of TAS-121, a novel, potent, and highly selective third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in Japanese patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) previously treated with EGFR-TKI. Methods This was an open-label, non-randomized, multi-center, dose escalation, phase I study conducted in three phases (dose escalation, expansion, and extension phases). TAS-121 was administered orally once daily (QD) or twice daily (BID) under fasting conditions in a 21-day treatment cycle. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-019-00732-4
Publisher Site
http://dx.doi.org/10.1007/s10637-019-00732-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856039PMC
December 2019
9 Reads

Prenatal exposure to pyrrolizidine alkaloids induced hepatotoxicity and pulmonary injury in fetal rats.

Reprod Toxicol 2019 04 13;85:34-41. Epub 2019 Feb 13.

Department of pharmacology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China; Hubei Provincial Key Laboratory of Developmentally Originated Diseases, Wuhan 430071, China. Electronic address:

Hepatic and pulmonary toxicity in fetal rats induced by pyrrolizidine alkaloids (PAs) was investigated. Retrorsine (RTS) or monocrotaline (MCT) was intragastrically administered during pregnancy. The reduction of body and tail lengths was consistent with body weight loss in PA-exposed fetuses, and pathological lesions in liver and lung were observed only in fetuses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.reprotox.2019.02.006DOI Listing
April 2019
25 Reads

Hepatotoxicity and Recurrent NSTEMI While on Pembrolizumab for Metastatic Giant Cell Bone Tumor.

Am J Med Sci 2019 04 29;357(4):343-347. Epub 2018 Nov 29.

Department of Medicine, University of Illinois Chicago, Chicago, Illinois; Division of Hematology/Oncology, University of Illinois Chicago, Chicago, Illinois.

We present the first reported case showing metastatic giant bone cell tumor being treated successfully with pembrolizumab after failing prior tyrosine kinase inhibitor therapy. Of note, the patient developed multiple systemic effects associated with checkpoint inhibitor use. One year after starting the checkpoint inhibitor (ICI), the patient also developed hepatitis that was confirmed by liver biopsy and pathology to be, in part, due to drug-mediated toxicity similar to prior ICI toxicity cases that have been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjms.2018.11.017DOI Listing
April 2019
9 Reads

A case report and literature review: previously excluded tuberculosis masked by amiodarone induced lung injury.

BMC Pharmacol Toxicol 2018 Dec 29;19(1):88. Epub 2018 Dec 29.

Institute of Physiology and Pharmacology, Lithuanian University of Health Sciences, A. Mickeviciaus str. 9, 44307, Kaunas, LT, Lithuania.

Background: Amiodarone is an antiarrhythmic drug which is used to treat and prevent several dysrhythmias. This includes ventricular tachycardia and fibrillation, wide complex tachycardia, as well as atrial fibrillation (AF) and paroxysmal supraventricular tachycardia. Amiodarone may prove to be the agent of choice where the patient is hemodynamically unstable and unsuitable for direct current (DC) cardioversion. Read More

View Article

Download full-text PDF

Source
https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s40360-018-0279-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311077PMC
December 2018
50 Reads

Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib.

BMC Cancer 2018 Oct 19;18(1):995. Epub 2018 Oct 19.

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryou-machi, Aoba-ku, Sendai, 980-8574, Japan.

Background: Ceritinib demonstrated a statistically significant effect on the progression-free survival versus chemotherapy in patients with advanced anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) as the first therapy or after previous treatment with crizotinib and one or two prior chemotherapy regimens in global phase 3 studies. However, some serious adverse effects related to ceritinib therapy were reported across these clinical studies. Among them, a grade 3 and 4 increase in hepatobiliary enzymes was one of the common adverse events related to treatment with ceritinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4913-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194610PMC
October 2018
15 Reads

Drug-Induced Interstitial Lung Disease: A Systematic Review.

J Clin Med 2018 Oct 15;7(10). Epub 2018 Oct 15.

North West Lung Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M6 8HD, UK.

Background: Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous agents, but the risk often only becomes apparent after the marketing authorisation of such agents.

Methods: In this PRISMA-compliant systematic review, we aimed to evaluate and synthesise the current literature on DIILD.

Results: Following a quality assessment, 156 full-text papers describing more than 6000 DIILD cases were included in the review. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2077-0383/7/10/356
Publisher Site
http://dx.doi.org/10.3390/jcm7100356DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209877PMC
October 2018
71 Reads